Patent Application
20110311443
The invention relates to a method for treating a cancerous and/or an inflammatory disease in a patient, a use of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs, a pharmaceutical composition for the treatment of a cancerous and/or an inflammatory disease in a patient, a method for identifying a cancerous and/or an inflammatory disease in a patient, a method of identifying at least one candidate for development of anti-cancerous or anti-inflammatory agents, a use of an antibody for preparing a pharmaceutical preparation or medicament for the treatment of prostate cancer, a composition or kit comprising at least one antibody and/or at least one ligand, and a biochip.
Among the non-cutaneous malignant neoplasm prostate cancer is the most common one in men in western countries. The disease accounts for the deaths of approx. 30,000 men per year in the USA. The pathogenesis of prostate cancer is unclear, although it was suggested that chronic inflammation is involved in the carcinogenesis. In the drive to find altered molecular pathways in the process of prostatic carcinogenesis, proteomics techniques have been applied to identify multiple changes in protein abundances simultaneously. In a recent study hundreds of proteins were found to be up-regulated in prostate cancer (TNM stages T1-T3), and dozens were found to be downregulated. Many of these proteins were suggested to account for aberrant behaviour of multiple signalling pathways in prostate cancer. An important question remains to be answered: Where are specific pathways and their networks located in situ and how are they structured? A proteomic technology addressing these features directly must be (i) non-destructive, (ii) able to visualize a large number of different molecular cell components (MCC) (preferentially proteins) simultaneously, and (iii) alignable with histological structures that can be readily examined in routine diagnostics working on light microscopic scales. The same considerations also apply to other cancerous and inflammatory diseases.
It is an object of the invention to ameliorate the identification and treatment of cancerous and/or inflammatory diseases.
The foregoing object is inventively achieved by a method according to claim 1 for treating a cancerous and/or an inflammatory disease in a patient. The object is also achieved through the uses of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs, a pharmaceutical composition according to claim 8 for the treatment of a cancerous and/or an inflammatory disease in a patient, a method according to claim 13 for identifying a cancerous and/or an inflammatory disease in a patient, a method according to claim 17 of identifying at least one candidate for development of anti-cancerous or anti-inflammatory agents, the use of an antibody for preparing a pharmaceutical preparation or medicament for the treatment of prostate cancer, a composition or kit according to claim 21, and a biochip according to claim 24.
Advantageous embodiments with expedient further developments of the invention are indicated in the corresponding subclaims.
An inventive method for treating a cancerous and/or an inflammatory disease in a patient comprises internally administering to the patient an effective amount of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29. CD26 and CD29 in this context are cell surface molecules that can be identified via the so-called “cluster of differentiation” or “cluster of designation” (abbreviated as CD) protocol. A protein cluster within the scope of the present disclosure is to be taken as combinatorial molecular phenotypes (CMPs) describing colocated and/or anti-colocated CDs, proteins and/or molecules in a certain place of a cell. Accordingly, groups of CMPs represent regions of colocated and/or anti-colocated CDs, proteins and/or molecules in a cell. The CMPs in this connection may for instance be indicated in the form of a binary code, with it being possible to encode via any digit of the binary number (i.e. via any “bit”) whether a predetermined protein/molecule is given in a certain place of the cell or in a concentration exceeding a certain limit value (1 or True), or else is not given in this place of the cell or only in a concentration falling short of a predetermined limit value (0 or False). The invention is based on the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore the cancerous and/or an inflammatory disease can effectively and without side-effects be cured by administering to the patient an effective amount of said pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29. In its most simple embodiment the pharmaceutical preparation used in the inventive method can be designed to block the biological activity of a CMP consisting of CD26 and/or CD29 only. A protein cluster or protein group (CMP) blocked by means of the inventive method besides CD26 and/or CD29 may in principle also comprise further CDs, proteins and/or molecules, for example one or more CDs and molecules as listed in the Supplementary Table (see Annex).
In a further aspect of the invention the patient is a human and/or an animal. In this context it has proven to be advantageous if said pharmaceutical preparation is designed to be type and/or species-specific.
In a further aspect of the invention the disease is prostate cancer. In this case the treatment of the patient with the pharmaceutical preparation—which is blocking the biological activity of the at least CD26 and/or CD29 comprising CMPs—has turned out to be particularly effective.
In a further aspect of the invention the pharmaceutical preparation is administered if a protein cluster (CMP) or a group of CMPs also containing CD44 and/or CD54 and/or CD138 and lacking at least one of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, and CD80 is identified on cell surfaces of cells obtained from an affected part of the body of the patient. In this way a particularly effective treatment of the cancerous and/or an inflammatory disease is ensured, so that in most cases it is sufficient to treat the patient with a low dose of the pharmaceutical preparation. The protein cluster or protein group (CMP) in principle may also lack several or all CDs form the group of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, and CD80.
In a further aspect of the invention said cells are obtained from a tissue block and/or a single tissue section, the tissue being removed from the prostate of the patient. This allows for a particularly simple and reliable test for the presence of the previously described CMPs and for the presence of prostrate cancer.
The invention in another aspect relates to a use of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29 for the treatment of a cancerous and/or an inflammatory disease in a patient by internally administering to the patient suffering such disease the pharmaceutical preparation in accordance with the method of any of the preceding claims. The invention is based on the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore the cancerous and/or an inflammatory disease can effectively and without side-effects be cured by use of said pharmaceutical preparation. In its most simple embodiment a pharmaceutical preparation can be used that blocks the biological activity of a CMP consisting of CD26 and/or CD29 only. A protein cluster or protein group (CMP) to be blocked by means of the pharmaceutical preparation may besides CD26 and/or CD29 in principle also comprise further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
The invention in another aspect relates to a use of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29 for the preparation of a medicament for the treatment of a cancerous and/or an inflammatory disease in a patient. The invention is based on the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore the cancerous and/or an inflammatory disease can be effectively and without side-effects be cured by a medicament comprising said pharmaceutical preparation. In its most simple embodiment the medicament may be designed to block the biological activity of a CMP consisting of CD26 and/or CD29 only. A protein cluster or protein group (CMP) to be blocked by means of the medicament besides CD26 and/or CD29 in principle may also comprise further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
Another embodiment of the invention provides a pharmaceutical composition for the treatment of a cancerous and/or an inflammatory disease in a patient comprising a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29. The invention in this regard is based on the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore the cancerous and/or an inflammatory disease can effectively and without side-effects be cured by use of said pharmaceutical preparation. In its most simple embodiment the pharmaceutical preparation may be designed to block the biological activity of a CMP consisting of CD26 and/or CD29 only. A protein cluster or protein group (CMP) to be blocked by means of the pharmaceutical preparation may besides CD26 and/or CD29 in principle also contain further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
In a further aspect of the invention, the cancerous disease to be treated is prostate cancer. In this case the pharmaceutical preparation—which is blocking the biological activity of the at least CD26 and/or CD29 comprising CMPs—has proven to be particularly effective.
In a further aspect of the invention, said pharmaceutical preparation comprises an antibody, preferably a monoclonal antibody, and/or a protein cross-linking agent and/or at least one of TSPAN4, CD9, Filamin, FLNB, CD81, CD46, MAP4K4, FHL2, NME1, PKC alpha, YWHAB, ITGB1BP1, LGALS8 and GNB2L1. This facilitates a particularly specific blocking of the biological activity of the at least one protein cluster (CMP) or group of CMPs. Moreover, the pharmaceutical preparation is also low in side-effects.
In another aspect of the invention, the pharmaceutical preparation comprises a pharmaceutically acceptable carrier. In the present invention, the pharmaceutically acceptable carrier depends on the concrete design of the pharmaceutical composition. A person skilled in the art can determine directly which pharmaceutically acceptable carrier can be used in the present invention. In one preferred embodiment, the pharmaceutically acceptable carrier is selected from physiological saline. The amount of the pharmaceutically acceptable carrier is generally from 0.1% by weight to 99.9% by weight, preferably from 5% by weight to 95% by weight, more preferably from 40% by weight to 90% by weight, and most preferably from 60% by weight to 80% by weight.
In another aspect of the invention, the pharmaceutical preparation is formulated for oral, parenteral, intravenous, intramuscular, buccal, transdermal or transmucosal route of administration, in immediate release form or in controlled release form. In this way the pharmaceutical preparation can be administered in a particularly flexible way and can be optimally adapted to the disease to be treated.
The invention in a further aspect relates to a method for identifying a cancerous and/or an inflammatory disease in a patient comprising at least the step of examining if at least a protein cluster (CMP) or a group of CMPs containing at least CD26 and/or CD29 can be identified on the cell surfaces of cells from a part of the body of the patient, wherein said part is suspected to be affected by said disease. The invention in this regard is based upon the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore, the inventive method allows for easy and reliably identification of a cancerous and/or an inflammatory disease. In its most simple embodiment the method according to the invention it may be tested for the presence of a CMP consisting of CD26 and/or CD29 only. In principle, though, it may also be tested for CMPs comprising besides CD26 and/or CD29 also further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
In another aspect of the invention, at least one protein cluster (CMP) or group of CMPs also containing CD44 and/or CD54 and/or CD138 and lacking at least one of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, and CD80 is identified on the cell surfaces of said cells. This represents a reliable indication of the presence of a cancerous and/or an inflammatory disease such as prostate cancer.
In another aspect of the invention, at least one protein cluster (CMP) or group of CMPs lacking at least one of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, CD80, CD44, CD54, and/or CD138 is identified on the cell surfaces of said cells. This represents a particularly reliable indication of the presence of a cancerous and/or an inflammatory disease such as prostate cancer. The protein cluster or protein group (CMP) in principle may also lack several or all CDs form the group of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, CD80, CD44, CD54, and/or CD138. A reliable indication of the presence of a cancerous and/or an inflammatory disease such as prostate cancer is given in further development of the invention in that the CMP is lacking at least CD44 and/or CD54 and/or CD138.
In another aspect of the invention, the disease is identified as prostate cancer if the cells derive from stroma and/or neoplastic epithelium of acini of prostate tissue and/or if at least 70%, preferably at least 75%, of the CMPs on the cell surface of at least one cell contain CD26 and/or CD29 and/or if at least 20%, preferably at least 35%, of the CMPs on the cell surface of at least one cell comprise CD26 and/or CD29 and lack at least CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, and CD80. In this way prostate cancer can be identified in a particularly simple and reliable way in the patient concerned.
Another embodiment of the invention provides a method of identifying at least one candidate for development of anti-cancerous or anti-inflammatory agents, comprising at least the step of examining if at least one protein cluster (CMP) or a group of CMPs containing at least CD26 and/or CD29 can be identified on the cell surfaces of cells from a part of the body of the patient, wherein said part of the body is suspected to be affected by a cancerous and/or inflammatory disease. The invention in this regard is based on the insight that CD26 and/or CD29 within the context of cancerous and/or inflammatory diseases are so-called “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore, the inventive method allows for easy and reliably identification of said candidate for development of agents directed against the cancerous and/or inflammatory disease said part of the body is affected by. In the most simple embodiment of the method according to the invention, it is tested for the presence of a CMP consisting of CD26 and/or CD29 only. In principle, though, it may also be tested for CMPs comprising besides CD26 and/or CD29 further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
In another aspect of the invention, said part of the body is prostate tissue and the disease is prostate cancer.
In another aspect of the invention, at least one protein cluster (CMP) or group of CMPs also containing CD44 and/or CD54 and/or CD138 and lacking at least one of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD49d, CD58, and CD80 is identified on the cell surfaces of said cells. This allows for a particularly reliable identification of a patient suffering from prostate cancer.
The invention in a further aspect relates to a use of a human and/or animal antibody, preferably a monoclonal antibody, directed against at least CD26 and/or CD29 for preparing a pharmaceutical preparation or medicament for the treatment of prostate cancer. As CD26 and/or CD29—as has already been set out before—in the context of prostate cancer are “lead proteins”, the use of an antibody according to the invention facilitates a treatment that is particularly specific and thus low in side-effects. In this connection in dependency on the species and type of the patient to be treated, a species-specific antibody can be selected, in order to avoid rejection reactions through the immune system. In principle one or more polyclonal, monoclonal, and/or recombinant antibodies may be used. Further, it may in principle be provided that at least one antibody also binds to CMPs comprising besides CD26 and/or CD29 also further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
Another embodiment of the invention provides a composition or kit comprising at least one antibody and/or at least one ligand wherein the antibody and/or ligand binds at least one cell surface protein selected from the group of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD26, CD29, CD38, CD44, CD49d, CD54, CD58, CD80 and CD138 and wherein the antibody and/or ligand is coupled with a label. The composition or kit can be used in one of the aforementioned methods. The composition or kit can also comprise propidium iodide or the like for localizing cell nuclei.
In another aspect of the invention, at least one label is a fluorescent dye, quantum dot, radioactive tag, spin label, binding tag for a second antibody and/or an enzyme. This allows for a flexible adaptation of the composition or kit to various applications and detection methods.
In another aspect of the invention, the composition or kit may be designed for use in a method for identifying a cancerous and/or an inflammatory disease in a patient.
Another embodiment of the invention provides a biochip for use in a method according to any of the preceding embodiments wherein at least one surface of the biochip comprises antibodies and/or ligands binding to a protein cluster (CMP) or a group of CMPs of cell surfaces of human and/or animal cells, wherein the CMP contains at least CD26 and/or CD29. In this regard the invention is based on the insight that CD26 and/or CD29 in the context of cancerous and/or inflammatory diseases are “lead proteins”. On a high level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to said CMP motifs), which are controlled by said lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. Therefore, the inventive biochip allows for easy and reliably identification of a cancerous and/or an inflammatory disease. In the most simple embodiment/design of the biochip according to the invention at least one surface may comprise antibodies and/or ligands, by means of which it can be tested for the presence of a CMP consisting of CD26 and/or CD29 only. In principle at least one surface of the biochip may be equipped with antibodies and/or ligands in such a way that it can also be tested for CMPs comprising besides CD26 and/or CD29 further CDs, proteins and/or molecules, for example one or more CDs and/or molecules as listed in the Supplementary Table (see Annex).
In another aspect of the invention, at least one surface of the biochip contains antibodies and/or ligands binding to a protein cluster (CMP) or a group of CMPs of cell surfaces of human and/or animal cells, wherein the CMP contains at least one of CD3, CD4, CD8, CD10, CD13, CD19, CD20, CD38, CD44, CD49d, CD54, CD58, CD80 and CD138. In this way for the identification of cancerous and/or inflammatory diseases important cell markers can be tested by means of the biochip according to the invention, so that a particularly fast and reliable diagnosis is facilitated.
Further features of the invention derive from the claims, the embodiments, as well as the drawings and tables. The features and feature combinations previously mentioned in the description as well as the features and feature combinations mentioned in the following in the embodiments can be used not only in the combination indicated in each case, but also in all other combinations or individually, without leaving the scope of the invention. It is shown in:
The microscopic fluorescence robot technology MELC/TIS is capable of imaging at least 100 different molecular cell components (MCCs) in one cell or tissue section. Multi-Epitope-Ligand-Cartography (MELC)/toponome imaging system (TIS) overcomes the spectral limitation of traditional fluorescence microscopy by using large dye-conjugated tag libraries and automatically bleaching a dye after imaging and re-labelling the same or another MCC in the identical sample with the same dye coupled to a tag having the same or another specificity, and repeat similar cycles with other tags for multiple times revealing multidimensional colocation patterns. By this approach, the so called toponome (the functional protein networks, or, the biological code of the cell) of a cell can be gathered. After the first description of the technology in 1990, the relevance of this approach to cell function has been increasingly recognized.
The MELC/TIS technology is unparalleled when it comes to the colocalization of a very large number of proteins using microscopy. The ability to colocalize proteins on a large scale is regarded as a bottleneck in the drive to understand how proteomes are organized in individual cells, and how interlocked clusters of proteins exert control over cellular functions. In the following examples MELC/TIS was used for the analysis of prostate tissue. By cyclical imaging of 17 different MCCs, 16 of which were cell surface proteins, the resulting high-dimensional protein colocation and anti-colocation code is described. Also, cell type specific protein clusters are visualized, and a protein cluster motif that is selectively expressed by neoplastic epithelial cells inside prostate acini is demonstrated.
Specimen. A single tissue was cut from a prostate tissue block of radical prostatectomy (61 yr old man with lymph node metastasis and histologically confirmed prostate cancer). The tissue block was removed from the peripheral zone of the prostate, containing multicentric foci of cancerous prostate acini and acini with features of low grade and high grade intraepithelial neoplasia (PIN).
Tag library. The tags used to label proteins and ligands in the tissue section, assembled as a toponome mapping library (MELC/TIS tag library), are summarized in Table 1. Table 1 shows a list of molecular cell components labelled in the following examples (column 1) together with their locus link annotations (columns 2 and 3) and the corresponding incubation imaging bleaching cycles (column 4). Column 3 gives some of the known cellular expressions and functions of the molecules illustrating why they were selected for the TIS procedure searching for their topological assemblies. The tags used for cyclical imaging procedures were either conjugated to FITC or PE, and signals of two tags per cycle were imaged. The molecules selected for the toponome imaging procedures in this study are all reference markers of the cell surface, which have all been calibrated for MELC/TIS in an earlier study. Some of the known cellular expressions and functions of these molecules are listed in column 3 of table 1 illustrating why these molecules were chosen for the TIS procedure.
Preparation of the tissue section. A five μm thick tissue section was cut from the prostate tissue block in a cryotome at −15° C. and placed on a large cover slip as described. The section was then fixed in acetone at room temperature (RT) for 10 seconds, air dried and stored at −80° C. until use. Before use (see MELC/TIS below), the section was again fixed in acetone (at −20° C.) for 10 min, air dried, and then rehydrated in PBS at RT. This was followed by incubation with normal goat serum for 30 min, and a washing step with PBS.
Optical parameters. To obtain an overview at 2D on the many cell types and their phenotypic variations present in the tissue, an optical set up was chosen, that was already successfully applied for the detection of protein clusters in other biological samples. For the MELC/TIS experiments (see below) a 16× oil objective with a numerical aperture of 0.5 was applied giving a pixel dimension of 850 nm×850 nm (=0.7225 μm) by using a two fold binning.
MELC/TIS. The features and functionalities of a MELC/TIS imaging robot have been described earlier. The procedure to run repetitive incubation imaging bleaching cycles (RIIBC) on the tissue section was as follows.
In brief, the cover slip with the tissue section (above) was placed on the stage of an inverted wide-field fluorescence microscope (Zeiss) equipped with fluorescence filters for fluoresceine-iso-thio-cyanate (FITC) and phycoerythrin (PE) (filter sets for FITC: excitation 480/40 BP; beam splitter 505 LP; emission 527/30 BP; filter sets for PE: excitation 546/11 BP; beam splitter 560 LP; emission 585/40 BP). For the cyclical imaging procedures, a given FITC- and PE-conjugated tag was merged in one cycle (Table 1, column on the right). Altogether 9 cycles were performed. Fluorochrome-labelled tags and wash solutions were added and removed robotically under temperature control (20° C.), avoiding any displacement of the sample and objective. In each cycle, two different tags, conjugated to either FITC or PE, were added (cycle sequence see table 1); phase contrast and fluorescence images were acquired by a high-sensitivity cooled CCD camera; the sample was washed with PBS and bleached at the excitation wavelengths; and post-bleaching phase contrast and fluorescence images were acquired. Data acquisition was fully automated using home made software. Note that interference of antibodies was avoided by permuting the cycle position of antibodies for optimal labelling results during the calibration procedure preceding the definitive measurements. The definitive sequence of cycles and molecules/proteins labelled per cycle is given in table 1. The sensitivity of the approach ranges between 500 and several thousand copies of the molecules labelled per cell, depending on the avidity of the used tags. Since monoclonal CD antibodies used in this study are extremely well characterized for their specificity in diagnostic medicine, we expect that positive signals indeed represent the molecules of interest. Hence false positive results can be excluded. We can not exclude that tissue sites, in which no signal is seen, do not contain the molecule of interest, which can be due to epitope masking resulting from conformational changes or binding of the corresponding epitope to interacting proteins.
Construction of a two-dimensional toponome map. Fluorescence images, produced by each tag, were aligned pixel-wise using the phase contrast images, with an in-register accuracy of +/−one pixel. Fluorescent pixels were then parsed by regarding the list of fluorescence intensities I1, I2, I3 . . . In for proteins 1, 2, 3 . . . n in any particular pixel or voxel as the values of an n-dimensional vector associated with that pixel. This vector can then be binarized by selecting thresholds T1, T2, T3 . . . Tn for proteins 1, 2, 3 . . . n, and setting the vector values for any protein m to zero if Im<Tm and to 1 if not, using thresholds manually set by human experts from within an automatically generated range. The binarized images were then combined to form a list of combinatorial molecular phenotypes (CMPs) representing the proteins/molecules expressed in each pixel, or groups of CMPs representing regions of interest. Given CMPs (protein clusters) or groups of CMPs were visualized in false colours at their location. We have established these steps in home made software, termed MoPPi (Modular Processing Pipeline).
Each signal within a CMP is mapped as tag present (=1) or tag absent (=0), depending on whether the value for the fluorescence signal is above or below this threshold, respectively (=1 bit information per protein at a pixel/voxel). CMPs assembled as a group will have unique features as defined by the assembly's lead proteins (L=1), absent proteins (A=anticolocated, 0) and wild card proteins (W=variably occurrence of a protein 0 and 1 in given CMPs of a CMP group). We define such CMP groups as a CMP motif (
In the present set up, with the optical parameters chosen (see material and methods section), a pixel expressing a given CMP, or protein cluster, has a dimension of 0.7225 μm.
Nine MELC/TIS cycles generate a gallery of 17 images. To illustrate working of toponomics in prostate cancer analysis, we have chosen a single tissue section of histologically verified prostatic cancer presenting as acinus type, with multifocal variations including presence of intraepithelial neoplasia (PIN). The results described henceforth were obtained by using the robot system MELC/TIS for the imaging of the toponome. To select a visual field for our study, a 16× oil phase contrast/fluorescence objective was used. Once the visual field was selected by an expert (
Localization of protein clusters (CMPs). As described in the material and methods section, we have applied our MoPPi software tool to (i) align the images from
Table 2 shows a coding list of the 30 most frequent distinct CMPs (out of 2,100 in total) detected in the visual field of
The expression/location of these CMPs in the tissue is shown in
Cell type specific protein clusters and protein cluster motifs. To provide a more detailed view of these CMP locations, a detail of
The most frequent CMPs of this area were then localized in different colours and as overlays with the CD138 fluorescence signal (
The colour coding (resp. grey scale) list for CMPs of
Table 3 (part I and part II) gives the corresponding colour or grey scale coding list of these CMPs. Table 3 part I shows a colour (resp. grey scale) coding list of the 25 most frequent CMPs (out of 2,100) which are selectively expressed by cell structures in the stroma surrounding neoplastic prostate acini. The CMPs are sorted according to their frequency (from top to bottom, high to lower) and expression of these CMPs in the stroma is shown in
In other words,
Notably, 25 CMPs are selectively expressed by cells in the stroma (Table 3, part I;
By following a strategy of extraction of the most prominent and relevant information contained in the many CMPs detected, each single CMP out of the 30 and 41 most frequent CMPs has been visualized. The CMPs are summarized in Tables 2 and 3, and in supplementary table 1, respectively. As shown in table 3 (part II), the most frequent CMPs within the PIN-CMP motif is CMP1 coexpressing the lead cell surface proteins CD29/CD26 together with CD54 and CD138, while all other 12 cell surface proteins are anti-colocated (=0) in that CMP. This CMP is indeed expressed in all except one of the acini undergoing neoplasia in the visual field (
As indicated by arrows, the location of this CMP is interesting, because it singles out apical (
Another prominent feature of the tissue analyzed in the present example is the striking selectivity of CMPs for non-epithelial cellular structures in the fibrocollagenous stroma surrounding the acini (
Together these major results are summarized in a scheme (
To sum up, these findings describe the feasibility to map a fraction of the cell surface toponome of proteins in a single tissue section in this disease. Accordingly, the present findings provide insight in protein networks driving the disease. The present approach has led to entirely structure-bound combinatorial data generating a new type of high-dimensional data space. Mapping the organized proteome by MELC/TIS in earlier studies revealed the structure-bound architecture of functional protein networks (the toponome). It has unravelled new cellular mechanisms and lead proteins controlling pathogenic networks in rhabdomyosarcoma cells. By colocalizing 17 different molecular components in one tissue sectionmore than 2,000 different protein clusters (CMPs) were detected, some of which are specifically associated as CMP motifs with the features of neoplasia (e.g. proliferative intraepithelial neoplasia, PIN). Also, CMP motifs selectively associated with inflammatory CD4 lymphocytes and capillary endothelium were detected. No specific motifs were found for stromal cells of the fibrocollagenous stroma surrounding prostate acini, and for inflammatory CD8 lymphocytes, while both these latter cell types did express several single marker proteins. Simple protein network graphs illustrate how these distinct features of differentially associated proteins are selectively displayed by these cell types (
These findings are in keep with our earlier observations, that CMP mapping rapidly leads to insight into relevant protein assemblies and the rules of their topological order, to address what we term the generative grammar of the toponome. Detection of clear-cut cell-type specific clustering of proteins in situ relies on the ability of MELC/TIS to co-map a quasi random number of proteins by cyclical imaging in any given data point of a digitized image of a tissue section in one procedure. Compared to the localization of only one or few proteins, this leads to an exponential increase of biological information, as shown in the present invention. Protein clusters (differential local combination of n proteins), rather than a single protein species, clearly distinguish cell types, subcellular sites, or, different functional states of a cell or a tissue. Moreover, on an even higher level of molecular cell organization, protein clusters are frequently interlocked as protein cluster networks (corresponding to CMP motifs), which are controlled by lead proteins: when the lead protein is inhibited, the clusters disassemble leading to loss of function. In the present invention a CMP motif has been found that is expressed inside prostate acini by epithelial cells with features of neoplasia (e.g. proliferative intraepithelial neoplasia, PIN) (PIN specific motif), while basal epithelial cells with inconspicuous features do not express this motif. This finding supports the toponome approach to new molecular pathways in prostate cancer.
First, the two lead proteins (CD29 and CD26) of the PIN-specific motif detected here are structurally and functionally distinct: CD29 is a beta integrin chain which associates as a heterodimer non-covalently with the alpha integrin chain subunit. The molecule is involved in cell-cell and cell-matrix interactions. The highly conserved cytoplasmic domain of CD29 interacts with the cytoskeleton. CD26 (dipeptidyl peptidase IV, DPPIV), is a type II transmembrane integral protein. It is a cell surface protease cleaving dipeptides from NH2-termini of proteins provided that the penultimate residue is proline. The distinct structure and function of these two proteins coexisting as lead proteins in all CMPs, or, protein clusters of the detected PIN motif, is consistent with our earlier observation in rhabdomyosarcoma cells, that supramolecular cell surface clusters are, by a rule, composed of highly dissimilar proteins.
Second, the detection of CD29 and CD26 and their corresponding motif singles out these proteins as candidates for therapeutic intervention in prostate cancer. Therefore, a blockade of these proteins, for example by cross-linking agents, interferes with the control of these proteins over the PIN motif, leading to its disassembly.
Third, the CMP motif clusters appear to be specific modules of the cell surface of PIN cells: by interaction with the cytoskeleton, for example through CD29, and through continuous proteolytic activity of CD26, the cluster is involved in PIN-specific cell polarization and migration. An intervention on the level of these two proteins therefore interferes with tumor progression. Given CD26 as a proteolytic lead protein enzyme, assembled with CD29 as an integrin in our present example, a new functional model emerges: cell surface enzymes are important lead elements interacting with cytoskeleton-linking proteins to exert control over topology and function of extended protein cluster networks.
Together, finding of tumour specific targets or target clusters, and understanding the molecular mechanisms of disease in situ is a major goal in cancer research. High-throughput transcriptomics and proteomics studies, based on ex vivo analyses, have already assembled many new information on interesting target candidates, and efficient methods for handling such high-dimensional data have been described. By contrast, the present invention addresses the architecture of protein networks directly in situ in the individual cell or tissue section. This leads to a different kind of high-dimensional data, with a topological mosaic of protein colocation and anti-colocation clusters. Construction of corresponding toponome reference maps of prostate cancer serves as the starting point in the search of disease-specific protein networks and lead proteins. Such reference maps can be used as a scaffold, or, assembly of combinatorial molecular landmarks, for the construction of much larger maps involving many more proteins.
The optical set up in the present study, with a pixel dimension of 0.7225 μm, was chosen to address in one visual filed as many cells and acini as possible, with a sufficient resolution to find protein clusters associated with cells and cell surfaces. However, if needed, the optical resolution of MELC/TIS can be substantially enhanced for any kind of analysis pinpointing protein clusters in pixels with a dimension of at least 0.0466 μm, as shown in detail in our earlier 2D and 3D studies.
The foregoing description of various aspects of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and modifications and variations are possible. Such modifications and variations are intended to be included within the scope of the invention as defined by the accompanying claims. The parameter values for the definition of processing and measuring conditions for the characterization of specific properties of the subject matter of the invention are to be regarded as comprised within the scope of the invention also within the limits of deviations—e.g. due to measuring errors, system errors, weighing errors, DIN tolerances and the like indicated in the documents.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2010/001254 | 3/1/2010 | WO | 00 | 8/31/2011 |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 61158083 | Mar 2009 | US |
| Child | 13254103 | US |
